Tuesday, February 9, 2010
SSRI Associated with Increased Breast Cancer
Here's the whole abstract:
Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study
Catherine M Kelly, medical oncology fellow 1,5, David N Juurlink, division head, clinical pharmacology1,2,3,4,5,7, Tara Gomes, epidemiologist7, Minh Duong-Hua, analyst6, Kathleen I Pritchard, professor1,2,3,5, Peter C Austin, senior statistician5,7, Lawrence F Paszat, senior scientist1,2,3,5,7
1 Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Canada, 2 Sunnybrook Research Institute, Toronto,, 3 Department of Medicine, University of Toronto, Toronto, 4 Department of Pediatrics, University of Toronto, 5 Department of Health Policy, Management, and Evaluation, University of Toronto, 6 Canadian Institute for Health Information, Toronto, 7 The Institute for Clinical Evaluative Sciences, Ontario, Canada
Correspondence to: D Juurlink, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada M4N 3M5 email@example.com
Objective To characterise whether some selective serotonin reuptake inhibitor (SSRI) antidepressants reduce tamoxifen’s effectiveness by inhibiting its bioactivation by cytochrome P450 2D6 (CYP2D6).
Design Population based cohort study.
Participants Women living in Ontario aged 66 years or older treated with tamoxifen for breast cancer between 1993 and 2005 who had overlapping treatment with a single SSRI.
Main outcome measures Risk of death from breast cancer after completion of tamoxifen treatment, as a function of the proportion of time on tamoxifen during which each SSRI had been co-prescribed.
Results Of 2430 women treated with tamoxifen and a single SSRI, 374 (15.4%) died of breast cancer during follow-up (mean follow-up 2.38 years, SD 2.59). After adjustment for age, duration of tamoxifen treatment, and other potential confounders, absolute increases of 25%, 50%, and 75% in the proportion of time on tamoxifen with overlapping use of paroxetine (an irreversible inhibitor of CYP2D6) were associated with 24%, 54%, and 91% increases in the risk of death from breast cancer, respectively (P<0.05 for each comparison). By contrast, no such risk was seen with other antidepressants. We estimate that use of paroxetine for 41% of tamoxifen treatment (the median overlap in our sample) would result in one additional breast cancer death within five years of cessation of tamoxifen for every 19.7 (95% confidence interval 12.5 to 46.3) patients so treated; the risk with more extensive overlap would be greater.
Conclusion Paroxetine use during tamoxifen treatment is associated with an increased risk of death from breast cancer, supporting the hypothesis that paroxetine can reduce or abolish the benefit of tamoxifen in women with breast cancer.
Gottfried Center for Integrative Medicine's Fan Box
Gottfried Center for Integrative Medicine on Facebook
- 30-day Joy Practice: Join Me!
- The Big "C" - How to Prevent Aggressively
- Patch That Leaky Gut
- Psychiatric Medications - Effects on Breastfeeding...
- Fantastic Interview with Tias Little
- Happy V-Day: Tantra 101 for Couples
- SSRI Associated with Increased Breast Cancer
- Open to Grace
- Trudie Styler: First Celebrity Cover of YJ
- Rest, Wisdom, Delight
- 10x10: Dr Northrup's Top 10 Women's Health Finding...
- ▼ February (11)
- ► 2009 (40)
- ► 2008 (24)
- Dr. Sara Gottfried, MD
- I'm an organic gynecologist, yoga teacher + writer. I earn a living partnering with women to get them vital and self-realized again. We're born that way, but often fall off the path. Let's take your lousy mood and fatigue, and transform it into something sacred and useful.